While the Paradigm study validated HMA-Venetoclax for fit, adverse-risk AML patients, it didn't alter practice at tertiary centers focused on curative transplant. However, it significantly empowered community oncologists by providing a viable, less toxic option beyond just referring patients to a specialty center or hospice.
The standard of care for AML has shifted from immediate induction chemotherapy to a "wait and profile" approach. Rushing to treat with a general therapy like HMA-Venetoclax before getting molecular results can be detrimental if the patient has a subtype highly curable with specific intensive chemotherapy.
The FLT3 inhibitor Quizartinib may benefit FLT3 wild-type AML patients who exhibit a specific gene expression profile indicating "FLT3 addiction." This is based on the rationale that FLT3 is overexpressed on all AML blasts, not just mutated ones, potentially doubling the drug's eligible patient population.
While newer, less toxic therapies like HMA-Venetoclax empower community oncologists to treat AML, this creates a new risk: failing to refer younger, curable patients to tertiary centers for allogeneic transplant, which remains the only curative option for many adverse-risk patients.
For elderly IDH1-mutated AML patients, Aza-Ivosidenib is often preferred over Aza-Venetoclax. It offers better neutrophil recovery in the first cycle and, critically, is not myelosuppressive in remission, eliminating the complex dose adjustments required with venetoclax and simplifying long-term management.
Differentiation syndrome (DS) in AML treatment clinically mimics infection or relapse. The correct approach is to treat both possibilities concurrently with broad-spectrum antibiotics and steroids. A rapid improvement following steroid administration retrospectively confirms the DS diagnosis.
Despite targeting core driver mutations NPM1 and KMT2A, Menin inhibitors as monotherapy show low (20-25%) and brief responses in AML. This subverts the expectation that targeting a primary driver would be highly curative (like arsenic in APL), suggesting these leukemias have other critical survival pathways.
For IDH1-mutated AML patients who have failed venetoclax—a notoriously difficult-to-treat population with a 3-4 month median survival—Eludacidinib has demonstrated some of the best-reported outcomes. This carves out a clear clinical niche for the drug in this specific salvage setting.